MM
ADPT icon

MQS Management’s Adaptive Biotechnologies ADPT Stock Holding History

MQS Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,033
Closed -$36.3K – 418
2024
Q2 		$36.3K Buy
+10,033
New +$31.8K 0.02% 408
2024
Q1 		– Sell
-19,251
Closed -$94.3K – 421
2023
Q4 		$94.3K Buy
+19,251
New +$87.8K 0.05% 424

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

MQS Management's ADPT Position: Q3 2024 in Review

MQS Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2024, closing a stake of 10,033 shares — an estimated $36.3K sold.

MQS Management first reported a position in ADPT in Q4 2023 and held it in 2 quarters. The position peaked at $94.3K in Q4 2023. 187 funds tracked by Wall St. Rank hold ADPT as of Q3 2024.

  • MQS Management reported no remaining Adaptive Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • MQS Management sold 10,033 Adaptive Biotechnologies shares in Q3 2024, an estimated $36.3K.
  • MQS Management first reported a position in Adaptive Biotechnologies in Q4 2023 and held it in 2 quarters.
  • MQS Management's Adaptive Biotechnologies position peaked at $94.3K in Q4 2023.
  • 187 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2024.

Based on MQS Management's 13F filing for Q3 2024, filed 5 Nov 2024.